{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:52:31Z","timestamp":1791481951860,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000875","name":"PEW Charitable Trusts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100296","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:25:40Z","timestamp":1787934340000},"page":"100296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemia"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-5375","authenticated-orcid":false,"given":"Roberta","family":"Buono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3421-0897","authenticated-orcid":false,"given":"Madhuri","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-0732","authenticated-orcid":false,"given":"Sarah J.","family":"Skuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4080-3613","authenticated-orcid":false,"given":"Ian B.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0884-3550","authenticated-orcid":false,"given":"Ishita","family":"Tarnekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9993-886X","authenticated-orcid":false,"given":"Izabelle Marie F.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-pin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0164-1948","authenticated-orcid":false,"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wertheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u2019ishah","family":"Bakayoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Kruidenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-2190","authenticated-orcid":false,"given":"Dequina A.","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said M.","family":"Sebti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-6079","authenticated-orcid":false,"given":"Angela G.","family":"Fleischman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6651-4213","authenticated-orcid":false,"given":"Cholsoon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-3735","authenticated-orcid":false,"given":"Martin","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-5162","authenticated-orcid":false,"given":"David A.","family":"Fruman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bneo.2026.100296_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.trecan.2016.07.001","article-title":"Targeting BCL-2-like proteins to kill cancer cells","volume":"2","author":"Cory","year":"2016","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2026.100296_bib2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","article-title":"Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax","volume":"7","author":"Leverson","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.bneo.2026.100296_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bneo.2026.100296_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100296_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100296_bib6","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1080\/10428194.2017.1366999","article-title":"Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies","volume":"59","author":"Grant","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.bneo.2026.100296_bib7","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.bneo.2026.100296_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bneo.2026.100296_bib9","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2026.100296_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bneo.2026.100296_bib11","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.bneo.2026.100296_bib12","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100296_bib13","article-title":"TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches","volume":"16","author":"Deshpande","year":"2026","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100296_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cancers18040659","article-title":"Management of acute myeloid leukemia: a review","volume":"18","author":"Jeurkar","year":"2026","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bneo.2026.100296_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"},{"issue":"8041","key":"10.1016\/j.bneo.2026.100296_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"issue":"516","key":"10.1016\/j.bneo.2026.100296_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","volume":"11","author":"Sharon","year":"2019","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.bneo.2026.100296_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092400","article-title":"Cotargeting of mitochondrial complex I and Bcl-2 shows antileukemic activity against acute myeloid leukemia cells reliant on oxidative phosphorylation","volume":"12","author":"Liu","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.bneo.2026.100296_bib19","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","article-title":"Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia","volume":"2","author":"Bosc","year":"2021","journal-title":"Nat Cancer"},{"issue":"7","key":"10.1016\/j.bneo.2026.100296_bib20","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-22-0601","article-title":"Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia","volume":"13","author":"Glytsou","year":"2023","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.bneo.2026.100296_bib21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc.2016.76","article-title":"The interplay between cell signalling and the mevalonate pathway in cancer","volume":"16","author":"Mullen","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.bneo.2026.100296_bib22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.trecan.2020.11.008","article-title":"Targeting the mevalonate pathway in cancer","volume":"7","author":"Juarez","year":"2021","journal-title":"Trends Cancer"},{"issue":"48","key":"10.1016\/j.bneo.2026.100296_bib23","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1038\/onc.2012.6","article-title":"Targeting tumor cell metabolism with statins","volume":"31","author":"Clendening","year":"2012","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.bneo.2026.100296_bib24","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1158\/1078-0432.CCR-20-1967","article-title":"Statins as anticancer agents in the era of precision medicine","volume":"26","author":"Longo","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100296_bib25","article-title":"Statins as anti-tumor agents: a paradigm for repurposed drugs","volume":"7","author":"Tripathi","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"issue":"445","key":"10.1016\/j.bneo.2026.100296_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaq1240","article-title":"Statins enhance efficacy of venetoclax in blood cancers","volume":"10","author":"Lee","year":"2018","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.bneo.2026.100296_bib27","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/2767-9764.CRC-23-0350","article-title":"Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL-1 inhibitors","volume":"3","author":"Juarez","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.bneo.2026.100296_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78315-0","article-title":"Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia","volume":"10","author":"Gimenez","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.bneo.2026.100296_bib29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3324\/haematol.2018.204701","article-title":"Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies","volume":"104","author":"Al-Zebeeby","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bneo.2026.100296_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100036","article-title":"A phase 1 study of adding pitavastatin to venetoclax-based therapy in AML and CLL\/SLL: a tolerable, mechanism-based, drug repurposing strategy","volume":"1","author":"Brem","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.bneo.2026.100296_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ctrv.2018.06.010","article-title":"The poor design of clinical trials of statins in oncology may explain their failure - Lessons for drug repurposing","volume":"69","author":"Abdullah","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bneo.2026.100296_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2025.10.003","article-title":"Beyond cardiovascular health: the pharmacotherapeutic potential of statins in oncology","volume":"117","author":"Abdelhamid","year":"2025","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100296_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrm.2015.11","article-title":"Protein prenylation: unique fats make their mark on biology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100296_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"issue":"29","key":"10.1016\/j.bneo.2026.100296_bib35","doi-asserted-by":"crossref","first-page":"11994","DOI":"10.1073\/pnas.1310656110","article-title":"TET1 plays an essential oncogenic role in MLL-rearranged leukemia","volume":"110","author":"Huang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bneo.2026.100296_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ebiom.2018.01.031","article-title":"High expression of TET1 predicts poor survival in cytogenetically normal acute myeloid leukemia from two cohorts","volume":"28","author":"Wang","year":"2018","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.bneo.2026.100296_bib37","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41375-025-02668-6","article-title":"Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response","volume":"39","author":"Skuli","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2026.100296_bib38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","author":"Teh","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bneo.2026.100296_bib39","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.bneo.2026.100296_bib40","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.leu.2402196","article-title":"Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells","volume":"15","author":"Xia","year":"2001","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2026.100296_bib41","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1535-7163.MCT-06-0745","article-title":"Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma","volume":"6","author":"Wong","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.bneo.2026.100296_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.08.070","article-title":"The mevalonate pathway is a druggable target for vaccine adjuvant discovery","volume":"175","author":"Xia","year":"2018","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bneo.2026.100296_bib43","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1039\/b517572k","article-title":"Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I","volume":"4","author":"Peng","year":"2006","journal-title":"Org Biomol Chem"},{"issue":"36","key":"10.1016\/j.bneo.2026.100296_bib44","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1038\/sj.onc.1204459","article-title":"A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors","volume":"20","author":"Schuldiner","year":"2001","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bneo.2026.100296_bib45","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1097-2765(03)00102-3","article-title":"Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss","volume":"11","author":"Baudino","year":"2003","journal-title":"Mol Cell"},{"issue":"29","key":"10.1016\/j.bneo.2026.100296_bib46","doi-asserted-by":"crossref","first-page":"26922","DOI":"10.18632\/oncotarget.4616","article-title":"Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma","volume":"6","author":"Kervo\u00eblen","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bneo.2026.100296_bib47","first-page":"2023","article-title":"Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin","volume":"8","author":"Newman","year":"1994","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bneo.2026.100296_bib48","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood-2006-08-044446","article-title":"Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study","volume":"109","author":"Kornblau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100296_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2018.01.021","article-title":"Report of the relapsed\/refractory cohort of SWOG S0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)","volume":"67","author":"Advani","year":"2018","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.bneo.2026.100296_bib50","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1194\/jlr.M067488","article-title":"Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice","volume":"57","author":"Schonewille","year":"2016","journal-title":"J Lipid Res"},{"issue":"19","key":"10.1016\/j.bneo.2026.100296_bib51","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1158\/0008-5472.CAN-24-0970","article-title":"Targeting cholesterol biosynthesis with statins synergizes with AKT inhibitors in triple-negative breast cancer","volume":"84","author":"Hillis","year":"2024","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.bneo.2026.100296_bib52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bneo.2026.100296_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(10)71063-1","article-title":"Pitavastatin - pharmacological profile from early phase studies","volume":"11","author":"Catapano","year":"2010","journal-title":"Atheroscler Suppl"},{"issue":"sup1","key":"10.1016\/j.bneo.2026.100296_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/clp.12.21","article-title":"Pitavastatin: a different pharmacological profile","volume":"7","author":"Catapano","year":"2012","journal-title":"Clin Lipidol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100296_bib55","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2026.100296_bib56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"10.1016\/j.bneo.2026.100296_bib57","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","article-title":"A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed\/refractory hematologic malignancies","volume":"30","author":"Desai","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bneo.2026.100296_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110197","article-title":"AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia","volume":"38","author":"Grenier","year":"2022","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.bneo.2026.100296_bib59","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bjh.18968","article-title":"Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway","volume":"202","author":"Hua","year":"2023","journal-title":"Br J Haematol"},{"issue":"32","key":"10.1016\/j.bneo.2026.100296_bib60","doi-asserted-by":"crossref","first-page":"51435","DOI":"10.18632\/oncotarget.9843","article-title":"Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport","volume":"7","author":"Velez","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bneo.2026.100296_bib61","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100296_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.bneo.2026.100296_bib63","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1158\/0008-5472.CAN-14-0130","article-title":"Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop","volume":"74","author":"Pandyra","year":"2014","journal-title":"Cancer Res"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802600107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802600107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:10:47Z","timestamp":1791479447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032802600107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S295032802600107X"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100296","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100296"}}